Genaera Discontinues Phase II Studies Of Lomucin And Squalamine
This article was originally published in The Pink Sheet Daily
Executive Summary
Termination of the studies reflects Genaera’s decision to focus on core assets trodusquemine for obesity and anti-IL-9 program for asthma.
You may also be interested in...
Genaera Shifts Focus From AMD To Obesity
Company switches gears in the wake of Genentech’s Lucentis launch.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.